Gene expression microarray analysis of early oxygen-induced retinopathy in the rat

Journal of Ocular Biology, Diseases, and Informatics

Volumn 2, Issue 4, 2009, Pages 190-201

  Tea, Melinda ^a   Fogarty, Rhys ^a   Brereton, Helen M ^a   Michael, Michael Z ^a   Van der Hoek, Mark B ^b   Tsykin, Anna ^b   Coster, Douglas J ^a   Williams, Keryn A ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Affymetrix microarray; Cyclic hyperoxia; Gene expression; Inbred rat; Oxygen induced retinopathy

Indexed keywords

MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; FISCHER 344 RAT; GENE EXPRESSION PROFILING; GENETIC SUSCEPTIBILITY; HISTOCHEMISTRY; HYPEROXIA; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETROLENTAL FIBROPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

EID: 76849109129     PISSN: None     EISSN: 19368445     Source Type: Journal    
DOI: 10.1007/s12177-009-9041-7     Document Type: Article

References (46)

1. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-82
2. Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991;98:1628-40
3. Early Treatment For Retinopathy Of Prematurity Cooperative G. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684-94
4. Holmstrom G, van Wijngaarden P, Coster DJ, Williams KA. Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies. Br J Ophthalmol. 2007;91:1704-8
5. Bizzarro MJ, Hussain N, Jonsson B, Feng R, Ment LR, Gruen JR, et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics. 2006;118:1858-63
6. Zacharias L. Retrolental fibroplasia; a survey. Am J Ophthalmol. 1952;35:1426-54
7. Ng YK, Fielder AR, Shaw DE, Levene MI. Epidemiology of retinopathy of prematurity. Lancet. 1988;2:1235-8
8. Saunders RA, Donahue ML, Christmann LM, Pakalnis AV, Tung B, Hardy RJ, et al. Racial variation in retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1997;115:604-8
9. Chan-Ling T, Stone J. Retinopathy of prematurity: origins in the architecture of the retina. Prog Retin Res. 1993;12:155-78
10. Rogers MS, D'Amato RJ. The effect of genetic diversity on angiogenesis. Exp Cell Res. 2006;312:561-74
11. van Wijngaarden P, Coster DJ, Brereton HM, Gibbins IL, Williams KA. Strain-dependent differences in oxygen-induced retinopathy in the inbred rat. Invest Ophthalmol Vis Sci. 2005;46:1445-52
12. van Wijngaarden P, Brereton HM, Coster DJ, Williams KA. Genetic influences on susceptibility to oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2007;48:1761-66
13. van Wijngaarden P, Brereton HM, Gibbins IL, Coster DJ, Williams KA. Kinetics of strain-dependent differential gene expression in oxygen-induced retinopathy in the rat. Exp Eye Res. 2007;85:508-17
14. Chan CK, Pham LN, Zhou J, Spee C, Ryan SJ, Hinton DR. Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization. Lab Invest. 2005;85:721-33
15. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:44-57.
16. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57.
17. Ventresca MR, Gonder JR, Tanswell AK. Oxygen-induced proliferative retinopathy in the newborn rat. Can J Ophthalmol. 1990;25:186-9.
18. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci. 1993;34:576-85.
19. Penn JS, Tolman BL, Henry MM. Oxygen-induced retinopathy in the rat: relationship of retinal nonperfusion to subsequent neovascularization. Invest Ophthalmol Vis Sci. 1994;35:3429-35.
20. Reynaud X, Dorey CK. Extraretinal neovascularization induced by hypoxic episodes in the neonatal rat. Invest Ophthalmol Vis Sci. 1994;35:3169-77.
21. Penn JS, Henry MM, Wall PT, Tolman BL. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci. 1995;36:2063-70.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57:289-300.
23. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132: 365-86.
24. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Invest Ophthalmol Vis Sci. 1994;35:3429-35.
25. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034. 1-.11.
26. van Wijngaarden P, Brereton HM, Coster DJ, Williams KA. Stability of housekeeping gene expression in the rat retina during exposure to cyclic hyperoxia. Mol Vis. 2007;13:1508-15.
27. Smith LE. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;S140(Suppl A):4.
28. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen- dependent proteolysis. Nature. 1999;399:271-5.
29. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275:25733-41. (Pubitemid 30687077)
30. Bracken CP, Whitelaw ML, Peet DJ. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cell Mol Life Sci. 2003;60:1376-93.
31. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279:38458-65.
32. Pescador N, Cuevas Y, Naranjo S, Alcaide M, Villar D, Landazuri MO, et al. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J. 2005;390:189-97.
33. Dioum EM, Clarke SL, Ding K, Repa JJ, Garcia JA. HIF- 2alphahaploinsufficient mice have blunted retinal neovascularization due to impaired expression of a proangiogenic gene battery. Invest Ophthalmol Vis Sci. 2008;49:2714-20.
34. Morita M,OhnedaO,Yamashita T, Takahashi S, Suzuki N, Nakajima O, et al. HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 2003;22:1134-46.
35. Recchia FM, Xu L, Penn JS, Boone B, Dexheimer P. Identification of genes and pathways involved in retinal neovascularization by microarray analysis of two animal models of retinal angiogenesis. Invest Ophthalmol Vis Sci. 2009. doi:10.1167/iovs.09-4006.
36. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996;271:32253-59.
37. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxiainducible factor-1 in the lung. Am J Physiol. 1998;275:L818-26.
38. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005;5:189-200.
39. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene. 2003;22:4734-44.
40. Bergersen L, Johannsson E, Veruki ML, Nagelhus EA, Halestrap A, Sejersted OM, et al. Cellular and subcellular expression of monocarboxylate transporters in the pigment epithelium and retina of the rat. Neuroscience. 1999;90:319-31.
41. Chidlow G, Wood JP, Graham M, Osborne NN. Expression of monocarboxylate transporters in rat ocular tissues. Am J Physiol Cell Physiol. 2005;288:C416-28.
42. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci. 2003;44:1305-11.
43. Olbryt M, Jarzab M, Jazowiecka-Rakus J, Simek K, Szala S, Sochanik A. Gene expression profile of B 16(F10) murine melanoma cells exposed to hypoxic conditions in vitro. Gene Expr. 2006;13:191-203.
44. Sato T, Kusaka S, Hashida N, Saishin Y, Fujikado T, Tano Y. Comprehensive gene-expression profile in murine oxygeninduced retinopathy. Br J Ophthalmol. 2009;93:96-103.
45. Natoli R, Provis J, Valter K, Stone J. Expression and role of the early-response gene Oxr1 in the hyperoxia-challenged mouse retina. Invest Ophthalmol Vis Sci. 2008;49:4561-67.
46. Sears JE, Hoppe G, Ebrahem Q, Anand-Apte B. Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy. Proc Natl Acad Sci USA. 2008;105:19898-903.